MediaPharma Srl is a preclinical stage biotech company that specializes in the research and development of monoclonal antibodies and Antibody-Drug Conjugates (ADCs). Their focus is on creating innovative therapeutic solutions for cancer and other severe diseases that currently have high unmet medical needs. The company emphasizes collaboration among scientists, doctors, and entrepreneurs, fostering a shared commitment to advancing medical science. MediaPharma has secured funding from various sources, including Filas Spa and the Italian Minister of Economic Development, which supports their innovative projects and technological advancements.

The company's product pipeline includes several promising candidates, all currently in the preclinical stage. Notable products include MP-EV20-ADC, an Anti-HER3 Antibody-Drug Conjugate, and MP-1959, an Anti-Gal-3BP Antibody, along with its ADC counterpart. These products are designed to enhance treatment efficacy and patient outcomes in oncology, showcasing MediaPharma's dedication to developing safe and effective therapies for challenging medical conditions.

Italy

MediaPharma Srl is a preclinical stage biotech company focusing on research and development of monoclonal antibodies, Antibody-Drug Conjugates (ADCs) and other products for the treatment of cancer and other severe diseases with high unmet medical needs. At MediaPharma, scientists, doctors and entrepreneurs share the same values and have been working together for years.

MediaPharma srl

Company Details